Secondary Logo

Institutional members access full text with Ovid®

On the Right Track, Finally?

Petitjeans, Fabrice, MD; Leroy, Sandrine, MD, PhD; Geloen, Alain, PhD; Pichot, Cyrille, MD; Ghignone, Marco, MD, FRCP, FCCP; Quintin, Luc, MD, PhD

doi: 10.1097/CCM.0000000000003653
Online Letters to the Editor
Buy

Department of Critical Care, Hopital Desgenettes, Lyon, France

Department of Epidemiology, EpiSmart, Basel, Switzerland

Department of Physiology, INSA de Lyon, France

Department of Critical Care, Hopital Louis Pasteur, Dole, France

Department of Critical Care, JF Kennedy North Campus, West Palm Beach, FL

Department of Critical Care, Hopital Desgenettes, Lyon, France

Dr. Quintin disclosed that he holds a US patent (8 846 606 B2, September 30, 2014: method and drug composition for treating septic shock hypotension), and he disclosed off-label product use of alpha-2 agonist (dexmedetomidine, clonidine) in the setting of septic shock to reduce noradrenaline requirements and inflammation. The remaining authors have disclosed that they do not have any potential conflicts of interest.

Copyright © by 2019 by the Society of Critical Care Medicine and Wolters Kluwer Health, Inc. All Rights Reserved.